Meeting
2015 ASCO Annual Meeting
A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors.
Authors
Christos Kyriakopoulos
University of Wisconsin Carbone Cancer Center, Madison, WI
Christos Kyriakopoulos , Jill Kolesar , Jens C. Eickhoff , Jennifer Heideman , Glenn Liu , Kari Braun Wisinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT01625156
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2554)
DOI
10.1200/jco.2015.33.15_suppl.2554
Abstract #
2554
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit
Poster
2013 ASCO Annual Meeting
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).
First Author: David Shao Peng Tan
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee